• Je něco špatně v tomto záznamu ?

Clinical predictors of non-response to lithium treatment in the Pharmacogenomics of Bipolar Disorder (PGBD) study

Y. Lin, AX. Maihofer, E. Stapp, M. Ritchey, N. Alliey-Rodriguez, A. Anand, Y. Balaraman, WH. Berrettini, H. Bertram, A. Bhattacharjee, CV. Calkin, C. Conroy, W. Coryell, N. D'Arcangelo, A. DeModena, JM. Biernacka, C. Fisher, N. Frazier, M. Frye,...

. 2021 ; 23 (8) : 821-831. [pub] 20210505

Jazyk angličtina Země Dánsko

Typ dokumentu klinické zkoušky, časopisecké články, multicentrická studie, Research Support, N.I.H., Extramural, práce podpořená grantem, Research Support, U.S. Gov't, Non-P.H.S.

Perzistentní odkaz   https://www.medvik.cz/link/bmc22019608

Grantová podpora
#64410 The Canadian Institutes of Health Research
I01 BX003431 BLRD VA - United States
U01 MH092758 NIMH NIH HHS - United States

BACKGROUND: Lithium is regarded as a first-line treatment for bipolar disorder (BD), but partial response and non-response commonly occurs. There exists a need to identify lithium non-responders prior to initiating treatment. The Pharmacogenomics of Bipolar Disorder (PGBD) Study was designed to identify predictors of lithium response. METHODS: The PGBD Study was an eleven site prospective trial of lithium treatment in bipolar I disorder. Subjects were stabilized on lithium monotherapy over 4 months and gradually discontinued from all other psychotropic medications. After ensuring a sustained clinical remission (defined by a score of ≤3 on the CGI for 4 weeks) had been achieved, subjects were followed for up to 2 years to monitor clinical response. Cox proportional hazard models were used to examine the relationship between clinical measures and time until failure to remit or relapse. RESULTS: A total of 345 individuals were enrolled into the study and included in the analysis. Of these, 101 subjects failed to remit or relapsed, 88 achieved remission and continued to study completion, and 156 were terminated from the study for other reasons. Significant clinical predictors of treatment failure (p < 0.05) included baseline anxiety symptoms, functional impairments, negative life events and lifetime clinical features such as a history of migraine, suicidal ideation/attempts, and mixed episodes, as well as a chronic course of illness. CONCLUSIONS: In this PGBD Study of lithium response, several clinical features were found to be associated with failure to respond to lithium. Future validation is needed to confirm these clinical predictors of treatment failure and their use clinically to distinguish who will do well on lithium before starting pharmacotherapy.

Center for Behavioral Health Cleveland Clinic Cleveland OH USA

Dalhousie University Halifax Canada

Department of Clinical Medicine Faculty of Medicine and Dentistry University of Bergen and Division of Psychiatry Haukeland University Hospital Bergen Norway

Department of Mental Health Johns Hopkins Bloomberg School of Public Health Baltimore MD USA

Department of Psychiatry and Behavioral Sciences The Johns Hopkins School of Medicine Baltimore MD USA

Department of Psychiatry Case Western Reserve University Cleveland OH USA

Department of Psychiatry Indiana University Indianapolis IN USA

Department of Psychiatry Massachusetts General Hospital and Harvard University Boston MA USA

Department of Psychiatry University of California San Diego La Jolla CA USA

Department of Psychiatry VA San Diego Healthcare System La Jolla CA USA

Division of Mental Health and Addiction Oslo University Hospital Oslo Norway

Division of Psychiatry Faculty of Medicine and Dentistry Stavanger University Hospital University of Bergen Stavanger Norway

Division of Psychiatry Haukeland University Hospital Bergen Norway

Division of Psychiatry St Olav University Hospital of Trondheim and Department of Neuroscience Faculty of Medicine Norwegian University of Science and Technology Trondheim Norway

Mayo Clinic Rochester MN USA

National Institute of Alcohol Abuse and Alcoholism NIH Bethesda MD USA

National Institute of Mental Health Klecany Czech Republic

Norwegian Centre for Mental Disorders Research Institute of Clinical Medicine University of Oslo Oslo Norway

University of Chicago Chicago IL USA

University of Iowa Iowa City IA USA

University of Michigan Ann Arbor MI USA

University of Pennsylvania Perelman School of Medicine Philadelphia PA USA

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22019608
003      
CZ-PrNML
005      
20220804135821.0
007      
ta
008      
220720s2021 dk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bdi.13078 $2 doi
035    __
$a (PubMed)33797828
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a dk
100    1_
$a Lin, Yian $u Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA $1 https://orcid.org/0000000263437942
245    10
$a Clinical predictors of non-response to lithium treatment in the Pharmacogenomics of Bipolar Disorder (PGBD) study / $c Y. Lin, AX. Maihofer, E. Stapp, M. Ritchey, N. Alliey-Rodriguez, A. Anand, Y. Balaraman, WH. Berrettini, H. Bertram, A. Bhattacharjee, CV. Calkin, C. Conroy, W. Coryell, N. D'Arcangelo, A. DeModena, JM. Biernacka, C. Fisher, N. Frazier, M. Frye, K. Gao, J. Garnham, E. Gershon, K. Glazer, FS. Goes, T. Goto, E. Karberg, G. Harrington, P. Jakobsen, M. Kamali, M. Kelly, SG. Leckband, FW. Lohoff, A. Stautland, MJ. McCarthy, MG. McInnis, F. Mondimore, G. Morken, JI. Nurnberger, KJ. Oedegaard, VEG. Syrstad, K. Ryan, M. Schinagle, H. Schoeyen, OA. Andreassen, M. Shaw, PD. Shilling, C. Slaney, B. Tarwater, JR. Calabrese, M. Alda, CM. Nievergelt, PP. Zandi, JR. Kelsoe
520    9_
$a BACKGROUND: Lithium is regarded as a first-line treatment for bipolar disorder (BD), but partial response and non-response commonly occurs. There exists a need to identify lithium non-responders prior to initiating treatment. The Pharmacogenomics of Bipolar Disorder (PGBD) Study was designed to identify predictors of lithium response. METHODS: The PGBD Study was an eleven site prospectiv $a BACKGROUND Lithium is regarded as a first line treatment for bipolar disorder BD but partial response and non response commonly occurs There exists a need to identify lithium non responders prior to initiating treatment The Pharmacogenomics of Bipolar Disorder PGBD Study was designed to identify predictors of lithium response METHODS The PGBD Study was an eleven site prospective trial of $a BACKGROUND: Lithium is regarded as a first-line treatment for bipolar disorder (BD), but partial response and non-response commonly occurs. There exists a need to identify lithium non-responders prior to initiating treatment. The Pharmacogenomics of Bipolar Disorder (PGBD) Study was designed to identify predictors of lithium response. METHODS: The PGBD Study was an eleven site prospective trial of lithium treatment in bipolar I disorder. Subjects were stabilized on lithium monotherapy over 4 months and gradually discontinued from all other psychotropic medications. After ensuring a sustained clinical remission (defined by a score of ≤3 on the CGI for 4 weeks) had been achieved, subjects were followed for up to 2 years to monitor clinical response. Cox proportional hazard models were used to examine the relationship between clinical measures and time until failure to remit or relapse. RESULTS: A total of 345 individuals were enrolled into the study and included in the analysis. Of these, 101 subjects failed to remit or relapsed, 88 achieved remission and continued to study completion, and 156 were terminated from the study for other reasons. Significant clinical predictors of treatment failure (p < 0.05) included baseline anxiety symptoms, functional impairments, negative life events and lifetime clinical features such as a history of migraine, suicidal ideation/attempts, and mixed episodes, as well as a chronic course of illness. CONCLUSIONS: In this PGBD Study of lithium response, several clinical features were found to be associated with failure to respond to lithium. Future validation is needed to confirm these clinical predictors of treatment failure and their use clinically to distinguish who will do well on lithium before starting pharmacotherapy.
650    12
$a bipolární porucha $x diagnóza $x farmakoterapie $x genetika $7 D001714
650    _2
$a lidé $7 D006801
650    _2
$a lithium $x terapeutické užití $7 D008094
650    _2
$a sloučeniny lithia $x terapeutické užití $7 D018020
650    _2
$a farmakogenetika $7 D010597
650    _2
$a prospektivní studie $7 D011446
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a Research Support, U.S. Gov't, Non-P.H.S. $7 D013486
700    1_
$a Maihofer, Adam X $u Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
700    1_
$a Stapp, Emma $u Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
700    1_
$a Ritchey, Megan $u Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
700    1_
$a Alliey-Rodriguez, Ney $u University of Chicago, Chicago, IL, USA
700    1_
$a Anand, Amit $u Center for Behavioral Health, Cleveland Clinic, Cleveland, OH, USA $1 https://orcid.org/0000000310166904
700    1_
$a Balaraman, Yokesh $u Department of Psychiatry, Indiana University, Indianapolis, IN, USA
700    1_
$a Berrettini, Wade H $u University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
700    1_
$a Bertram, Holli $u University of Michigan, Ann Arbor, MI, USA
700    1_
$a Bhattacharjee, Abesh $u Department of Psychiatry, VA San Diego Healthcare System, La Jolla, CA, USA
700    1_
$a Calkin, Cynthia V $u Dalhousie University, Halifax, Canada
700    1_
$a Conroy, Carla $u Department of Psychiatry, Case Western Reserve University, Cleveland, OH, USA
700    1_
$a Coryell, William $u University of Iowa, Iowa City, IA, USA $1 https://orcid.org/0000000339897276 $7 xx0104436
700    1_
$a D'Arcangelo, Nicole $u Department of Psychiatry, Case Western Reserve University, Cleveland, OH, USA
700    1_
$a DeModena, Anna $u Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
700    1_
$a Biernacka, Joanna M $u Mayo Clinic, Rochester, MN, USA $1 https://orcid.org/0000000193504440
700    1_
$a Fisher, Carrie $u Department of Psychiatry, Indiana University, Indianapolis, IN, USA
700    1_
$a Frazier, Nicole $u University of Michigan, Ann Arbor, MI, USA
700    1_
$a Frye, Mark $u Mayo Clinic, Rochester, MN, USA
700    1_
$a Gao, Keming $u Department of Psychiatry, Case Western Reserve University, Cleveland, OH, USA $1 https://orcid.org/0000000311302461
700    1_
$a Garnham, Julie $u Dalhousie University, Halifax, Canada
700    1_
$a Gershon, Elliot $u University of Chicago, Chicago, IL, USA
700    1_
$a Glazer, Kara $u Department of Psychiatry and Behavioral Sciences, The Johns Hopkins School of Medicine, Baltimore, MD, USA
700    1_
$a Goes, Fernando S $u Department of Psychiatry and Behavioral Sciences, The Johns Hopkins School of Medicine, Baltimore, MD, USA
700    1_
$a Goto, Toyomi $u Department of Psychiatry, Case Western Reserve University, Cleveland, OH, USA
700    1_
$a Karberg, Elizabeth $u Department of Psychiatry, Case Western Reserve University, Cleveland, OH, USA
700    1_
$a Harrington, Gloria $u University of Michigan, Ann Arbor, MI, USA
700    1_
$a Jakobsen, Petter $u Division of Psychiatry, Haukeland University Hospital, Bergen, Norway
700    1_
$a Kamali, Masoud $u University of Michigan, Ann Arbor, MI, USA $u Department of Psychiatry, Massachusetts General Hospital and Harvard University, Boston, MA, USA
700    1_
$a Kelly, Marisa $u University of Michigan, Ann Arbor, MI, USA
700    1_
$a Leckband, Susan G $u Department of Psychiatry, VA San Diego Healthcare System, La Jolla, CA, USA
700    1_
$a Lohoff, Falk W $u National Institute of Alcohol Abuse and Alcoholism, NIH, Bethesda, MD, USA
700    1_
$a Stautland, Andrea $u Department of Clinical Medicine, Faculty of Medicine and Dentistry, University of Bergen and Division of Psychiatry, Haukeland University Hospital, Bergen, Norway
700    1_
$a McCarthy, Michael J $u Department of Psychiatry, University of California San Diego, La Jolla, CA, USA $u Department of Psychiatry, VA San Diego Healthcare System, La Jolla, CA, USA
700    1_
$a McInnis, Melvin G $u University of Michigan, Ann Arbor, MI, USA
700    1_
$a Mondimore, Francis $u Department of Psychiatry and Behavioral Sciences, The Johns Hopkins School of Medicine, Baltimore, MD, USA
700    1_
$a Morken, Gunnar $u Division of Psychiatry, St. Olav University Hospital of Trondheim and Department of Neuroscience, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
700    1_
$a Nurnberger, John I $u Department of Psychiatry, Indiana University, Indianapolis, IN, USA $1 https://orcid.org/0000000276741767
700    1_
$a Oedegaard, Ketil J $u Department of Clinical Medicine, Faculty of Medicine and Dentistry, University of Bergen and Division of Psychiatry, Haukeland University Hospital, Bergen, Norway
700    1_
$a Syrstad, Vigdis Elin Giever $u Department of Clinical Medicine, Faculty of Medicine and Dentistry, University of Bergen and Division of Psychiatry, Haukeland University Hospital, Bergen, Norway
700    1_
$a Ryan, Kelly $u University of Michigan, Ann Arbor, MI, USA
700    1_
$a Schinagle, Martha $u Department of Psychiatry, Case Western Reserve University, Cleveland, OH, USA
700    1_
$a Schoeyen, Helle $u Division of Psychiatry, Faculty of Medicine and Dentistry, Stavanger University Hospital, University of Bergen, Stavanger, Norway
700    1_
$a Andreassen, Ole A $u Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway $u Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway
700    1_
$a Shaw, Marth $u University of Iowa, Iowa City, IA, USA
700    1_
$a Shilling, Paul D $u Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
700    1_
$a Slaney, Claire $u Dalhousie University, Halifax, Canada
700    1_
$a Tarwater, Bruce $u University of Iowa, Iowa City, IA, USA
700    1_
$a Calabrese, Joseph R $u Department of Psychiatry, Case Western Reserve University, Cleveland, OH, USA
700    1_
$a Alda, Martin $u Dalhousie University, Halifax, Canada $u National Institute of Mental Health, Klecany, Czech Republic $1 https://orcid.org/0000000195443944 $7 xx0072985
700    1_
$a Nievergelt, Caroline M $u Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
700    1_
$a Zandi, Peter P $u Department of Psychiatry and Behavioral Sciences, The Johns Hopkins School of Medicine, Baltimore, MD, USA $1 https://orcid.org/0000000184232623
700    1_
$a Kelsoe, John R $u Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
773    0_
$w MED00007648 $t Bipolar disorders $x 1399-5618 $g Roč. 23, č. 8 (2021), s. 821-831
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33797828 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135814 $b ABA008
999    __
$a ok $b bmc $g 1822993 $s 1170851
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 23 $c 8 $d 821-831 $e 20210505 $i 1399-5618 $m Bipolar disorders $n Bipolar Disord $x MED00007648
GRA    __
$a #64410 $p The Canadian Institutes of Health Research
GRA    __
$a I01 BX003431 $p BLRD VA $2 United States
GRA    __
$a U01 MH092758 $p NIMH NIH HHS $2 United States
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace